KEMSA: Pharmacist Leadership Boosts Medicine Availability in Kenya

• The Kenyan government and KEMSA are advocating for enhanced pharmacist leadership to improve the availability of essential medicines.
• Principal Secretary Dr. Ouma Oluga emphasized that pharmacists must strategically determine product needs, quantities, and procurement timing using data.
• KEMSA CEO Dr. Waqo Ejersa stated that supply chain success should be measured by patient access, not just procurement volume.
• The initiative aims to strengthen accountability, improve forecasting, and optimize inventory management across Kenya's health product supply chain.
• A conference in Naivasha brought together stakeholders to discuss these reforms and explore digital tools for supply chain visibility.

The ultimate measure of supply chain performance, according to Dr. Oluga, is whether patients can readily access the essential products they require.

A significant call for enhanced pharmacist leadership, coupled with evidence-based planning for health products, has been issued by the Kenyan government and the Kenya Medical Supplies Authority (KEMSA). The objective is to substantially improve the availability of essential health products and technologies (HPTs) across the nation. These pronouncements were made in Naivasha on October 13, during a five-day conference focused on "Strengthening Pharmacist Leadership and Strategic HPT Management for Sustainable Health System Resilience," which convened various stakeholders from October 11 to 15.

Dr. Ouma Oluga, the Principal Secretary for Medical Services, underscored that the effective management of medicines and other health products is foundational to delivering high-quality healthcare and achieving Universal Health Coverage. He stressed that simply procuring items does not guarantee their availability to patients when and where they are needed. This perspective highlights a critical gap that pharmacists are now expected to fill, moving beyond traditional roles to more strategic involvement in the entire supply chain. KEMSA Chief Executive Officer, Dr. Waqo Ejersa, echoed this sentiment, emphasizing that the ultimate measure of supply chain performance should be patient access, rather than merely the volume of products acquired.

Principal Secretary Dr. Oluga articulated a clear vision for pharmacists, positioning them at the core of determining which products are necessary, in what quantities, and precisely when they should be procured. This strategic input must be grounded in robust consumption data, clinical evidence, and specific service requirements. He further elaborated on the need for improved quantification and forecasting, rational utilization of medicines, efficient inventory management, and stronger accountability mechanisms throughout the health products supply chain. Such measures are intended to ensure that public resources are directed effectively towards meeting actual patient and facility needs.

Dr. Ejersa reinforced the idea that pharmacists are pivotal contributors across multiple facets of the supply chain, including forecasting, procurement, resource allocation, inventory management, and institutional decision-making. He urged hospitals to integrate pharmacists more deeply into the process of identifying health product requirements and managing related expenditures. The expertise of pharmacists, he noted, is indispensable for evidence-based planning, ensuring accountability, and continuous monitoring. Procurement decisions, according to Dr. Ejersa, must be informed by validated consumption data, current stock levels, service workload, and anticipated demand to enhance medicine availability and mitigate wastage, expiries, and avoidable costs.

The government's initiative also calls for closer coordination between KEMSA and health facilities. Dr. Oluga highlighted that timely and accurate information flowing from hospitals is essential for effective national procurement planning. Conversely, health facilities depend on a predictable and responsive supply of medicines and other essential health products to maintain uninterrupted service delivery. Dr. Ejersa warned that deficiencies in quantification, incomplete information, or delayed communication can severely impact product availability and lead to suboptimal use of public resources.

To address these challenges, both officials advocated for sustained engagement between KEMSA and health facilities, characterized by shared information, clearly defined responsibilities, and joint monitoring of supply chain performance. The Naivasha conference also served as a platform to explore opportunities for harmonizing health products, considering variations in strengths, dosage forms, pack sizes, and specifications where standardization is feasible without compromising clinical or operational integrity. Furthermore, participants examined the potential of digital tools to enhance visibility across the supply chain, improve consumption monitoring, and strengthen forecasting and inventory management practices.

Lawyers advising pharmaceutical companies, healthcare providers, or those involved in public procurement in Kenya should note the increased emphasis on pharmacist leadership, evidence-based procurement, and accountability within the KEMSA supply chain. This signals a potential shift in compliance expectations, contractual requirements, and risk assessment related to medicine supply and distribution, requiring closer scrutiny of data, forecasting, and inventory management practices.

Source: Reporting based on statements from government and KEMSA officials.